• Citer

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

par Strumberg, Dirk;Richly, Heike;Hilger, Ralf A;Schleucher, Norbert;Korfee, Sonke;Tewes, Mitra;Faghih, Markus;Brendel, Erich;Voliotis, Dimitris;Haase, Claus G;Schwartz, Brian;Awada, Ahmad ;Voigtmann, Rudolf;Scheulen, M E;Seeber, Siegfried
Référence Journal of clinical oncology, 23, 5, page (965-972)
Publication Publié, 2005-02

Article révisé par les pairs

• Détails
• Contenu

Titre:	Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Auteur:	Strumberg, Dirk; Richly, Heike; Hilger, Ralf A; Schleucher, Norbert; Korfee, Sonke; Tewes, Mitra; Faghih, Markus; Brendel, Erich; Voliotis, Dimitris; Haase, Claus G; Schwartz, Brian; Awada, Ahmad; Voigtmann, Rudolf; Scheulen, M E; Seeber, Siegfried
Informations sur la publication:	Journal of clinical oncology, 23, 5, page (965-972)
Statut de publication:	Publié, 2005-02
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adolescent
	Adult
	Aged
	Antineoplastic Agents -- administration & dosage
	Antineoplastic Agents -- adverse effects
	Antineoplastic Agents -- pharmacokinetics
	Benzenesulfonates -- administration & dosage
	Benzenesulfonates -- pharmacokinetics
	Carcinoma, Hepatocellular -- drug therapy
	Cohort Studies
	Colonic Neoplasms -- drug therapy
	Diarrhea -- chemically induced
	Extracellular Signal-Regulated MAP Kinases -- drug effects
	Fatigue -- chemically induced
	Female
	Humans
	Liver Neoplasms -- drug therapy
	Lymphocytes -- drug effects
	Lymphocytes -- enzymology
	Male
	Middle Aged
	Phosphatidylethanolamine Binding Protein -- administration & dosage
	Phosphatidylethanolamine Binding Protein -- adverse effects
	Phosphatidylethanolamine Binding Protein -- pharmacokinetics
	Phosphorylation -- drug effects
	Protein Kinase Inhibitors -- administration & dosage
	Protein Kinase Inhibitors -- adverse effects
	Protein Kinase Inhibitors -- pharmacokinetics
	Pyridines -- administration & dosage
	Pyridines -- pharmacokinetics
	Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
	Rectal Neoplasms -- drug therapy
	Safety
Note générale:	Clinical Trial
	Clinical Trial, Phase I
	Journal Article
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2005.06.124
	info:pii/JCO.2005.06.124
	info:scp/20044382799
	info:pmid/15613696